Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$49.67 USD
+2.62 (5.57%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $49.67 0.00 (0.00%) 6:00 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Brokerage Reports
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 321 - 340 ( 367 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Overcorrection, Extended Patent Protection - Upgrading Stock.
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Overcorrection, Extended Patent Protection - Upgrading Stock.
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q11 Results Review: Timelines on Track; Tweaks Sample Container and Marker Panel
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q11 Results In-Line - Validation Data on Track for 4Q Release
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Fair Value Reached - Lowering Rating to Market Perform
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Fair Value Reached - Lowering Rating to Market Perform
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q11 Financial Preview Reaffirming OUTPERFORM Rating Expecting Slightly Positive Test Design,
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Reaffirming OUTPERFORM Following Meetings with Management; Encouraged by CMS Dialogue Among Other Things
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q11 Results Review: No Surprises; Key Upcoming Milestones and Events On-Track
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Strong Progress On Upcoming Pivotal Clinical Trial - BUY
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J